Who Owns Alfresa Holdings Company?

Alfresa Holdings Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Controls Alfresa Holdings?

Unraveling the ownership structure of Alfresa Holdings is key to understanding its influence within Japan's dynamic healthcare sector. Formed in 2003 through a strategic merger, Alfresa Holdings has evolved into a major player in pharmaceutical distribution. Knowing the Alfresa Holdings SWOT Analysis is crucial for investors.

This analysis will explore the evolution of Alfresa ownership, examining its founding and the current Alfresa Holdings shareholders. We'll delve into key institutional investors and public shareholders, providing a comprehensive view of the company's control and strategic direction within the Japanese pharmaceutical market. Understanding Alfresa stock and its stakeholders is vital for anyone assessing the company's long-term prospects and its position within the healthcare industry in Japan.

The establishment of Alfresa Holdings Corporation in October 2003 marked a significant consolidation in the Japanese pharmaceutical distribution sector. This formation involved a stock transfer that combined AZWELL Inc. and Fukujin Co., Ltd., setting the stage for a major player in the healthcare industry in Japan. Understanding the founders and early ownership of Alfresa Holdings is key to grasping its strategic origins and subsequent growth.

The roots of Alfresa Holdings extend back to several historical entities, including Nippon Shoji Kaisha, Ltd., founded in 1939, and Fukujin Shoten Corporation, established in 1949. These companies, along with Taishodo Co., Ltd., which dates back to 1913, played crucial roles in the evolution of Alfresa. The early ownership structure reflects the integration of these businesses, with their respective shareholders and leadership contributing to the initial ownership of Alfresa Holdings.

The precise details of the initial equity splits and specific founders are not readily available in public records. However, the reorganization in October 2004, which created Alfresa Corporation and Alfresa Pharma Corporation, indicates a strategic alignment among the founding entities. This consolidation aimed to build a larger, more integrated healthcare consortium, reflecting a vision for expansion and enhanced market presence within the Japanese pharmaceutical market.

Key Founding Entities

AZWELL Inc. (merger of Nippon Shoji and Showa Pharmaceuticals)

Key Founding Entities

Fukujin Co., Ltd. (formerly Fukujin Shoten Corporation)

Key Founding Entities

Taishodo Co., Ltd.

Initial Structure

Stock transfer between AZWELL Inc. and Fukujin Co., Ltd.

Reorganization (Oct 2004)

Creation of Alfresa Corporation and Alfresa Pharma Corporation

Strategic Goal

To build a larger, more integrated healthcare consortium.

Early Ownership Dynamics

The early ownership of Alfresa Holdings was shaped by the integration of several key pharmaceutical and wholesale businesses. The initial structure involved the shareholders and leadership of AZWELL Inc., Fukujin Co., Ltd., and Taishodo Co., Ltd. The strategic consolidation aimed to create a stronger presence in the Japanese pharmaceutical market. For more details on the company's market position, you can read about the Target Market of Alfresa Holdings.

• The formation involved the merger of AZWELL Inc. and Fukujin Co., Ltd.
• The reorganization in 2004 led to the creation of Alfresa Corporation and Alfresa Pharma Corporation.
• The early ownership structure reflects the integration of existing pharmaceutical and wholesale businesses.
• The strategic goal was to create a larger, more integrated healthcare consortium.

Alfresa Holdings SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Understanding the ownership structure of Alfresa Holdings is crucial for investors and stakeholders. As of March 31, 2025, the company's shares are primarily held by institutional investors, reflecting its position in the Japanese pharmaceutical distribution and healthcare industry. The company's stock is listed on the Tokyo Stock Exchange (Prime Market), making it accessible to a wide range of investors interested in the Japanese pharmaceutical market.

The evolution of Alfresa ownership has been shaped by strategic moves to enhance its market position. Alfresa Holdings has made acquisitions and formed alliances to strengthen its operations. These actions have influenced its structure and market presence, aligning with its strategy to bolster its total supply chain services and expand into new healthcare segments. For more detailed information, you can explore Revenue Streams & Business Model of Alfresa Holdings.

Alfresa Holdings' ownership structure is a key aspect of its operations. The company's shareholder base includes significant institutional investors, underscoring its importance in the Japanese pharmaceutical distribution sector. The company's strategic acquisitions and alliances, like the acquisition of Ark Medical Solutions Inc. in September 2024 and business alliances with KORTUC INC. and GEXVal Inc. in December 2024, are aimed at enhancing its market position and expanding its healthcare offerings. These moves reflect the company's ongoing efforts to adapt and grow within the dynamic healthcare industry in Japan.

Key Takeaways on Alfresa Ownership

Alfresa Holdings' ownership is dominated by institutional investors, with The Master Trust Bank of Japan, Ltd. being the largest shareholder.

• Strategic acquisitions, such as Ark Medical Solutions Inc., are aimed at strengthening its market position.
• Alliances with companies like KORTUC INC. and GEXVal Inc. are part of its expansion strategy.
• The company's stock is publicly traded on the Tokyo Stock Exchange.
• Understanding Alfresa ownership is vital for investors in the Japanese pharmaceutical market.

Alfresa Holdings PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of May 15, 2025, the Board of Directors of Alfresa Holdings consists of several key figures. Ryuji Arakawa serves as Representative Director & President, while Yusuke Fukujin is Representative Director & Executive Vice President, overseeing the Ethical Pharmaceuticals Wholesaling Business & International Business. Other directors include Shigeki Ohashi, who holds the position of Director, Vice President & Executive Officer, Group Business Strategy, and Toshiki Tanaka, Director, Vice President & Executive Officer, Corporate Administration. The board also includes outside directors such as Koichi Shimada, Manabu Kinoshita, and Toshie Takeuchi.

Alfresa Holdings is preparing to transition from an audit and supervisory board structure to an audit and supervisory committee structure, pending shareholder approval at the June 25, 2025, Ordinary General Meeting. This change aims to clarify responsibilities in managerial decision-making and business execution. The company plans to have a maximum of 12 directors, excluding Audit & Supervisory Committee members, and no more than 5 directors who are Audit & Supervisory Committee members.

The voting structure at Alfresa Holdings follows a one-share-one-vote principle, ensuring all shareholders can exercise their rights. Institutional investors, such as The Master Trust Bank of Japan, Ltd. (Trust Account), hold significant voting power, with a 14.8% stake as of March 31, 2025. The company utilizes an Electronic Voting Platform for Foreign and Institutional Investors to facilitate voting. For more insights into the company's strategic approach, consider reading about the Marketing Strategy of Alfresa Holdings.

Key Takeaways on Alfresa Holdings

The Board of Directors is key to understanding Alfresa ownership and strategic direction.

• The company is transitioning its governance structure.
• Institutional investors have a significant influence on Alfresa stock.
• The board includes a mix of internal and external directors.
• The company is a major player in the Japanese pharmaceutical market.

Alfresa Holdings Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Alfresa Holdings has implemented several strategic initiatives impacting its ownership structure and operational framework. In November 2024, the company initiated a share buyback program aimed at improving capital efficiency and boosting shareholder returns. This resulted in the acquisition of 5,113,000 shares for ¥10,999 million by February 2025. Further demonstrating its commitment to capital optimization, the company retired 11,540,000 shares of treasury stock in March 2025. This action was part of a broader strategy to repurchase up to 6 million shares.

These moves reflect a focus on enhancing shareholder value and refining the capital structure. These actions are significant for Alfresa ownership, as they directly affect the outstanding shares and the distribution of ownership among shareholders. These changes are crucial for investors and stakeholders interested in the Alfresa stock and its future performance within the Japanese pharmaceutical market and the broader healthcare industry Japan.

The company has been actively involved in mergers and acquisitions and strategic alliances to strengthen its market position. These include the acquisition of Ark Medical Solutions Inc. in September 2024, and business and capital alliances with KORTUC INC. and GEXVal Inc. in December 2024. Moreover, in May 2024, a capital alliance with Morikubo CA Medical Inc. was established. These strategic moves indicate an expansion into specialized healthcare areas and a strengthening of its total supply chain services.

Key Developments

Share buybacks and treasury stock retirements indicate a focus on capital efficiency. Strategic alliances and acquisitions aim to expand into specialized healthcare areas. Leadership changes and governance enhancements are also underway.

Ownership Trends

Increased institutional ownership, including major trust banks and international investors. Ongoing share buybacks suggest a focus on optimizing capital structure. Strategic investments signal expansion within the healthcare consortium.

Corporate Governance

Transition to a company with an Audit and Supervisory Committee structure. This change, subject to shareholder approval, aims to enhance governance. Leadership changes, effective April 1, 2025, also reflect evolving governance.

Market Position

These developments are crucial for understanding Alfresa Holdings' strategic direction. For more detailed information, you can read this article about Alfresa Holdings.

Alfresa Holdings Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs